F5 Gets Price Target Cuts By Analysts After Q2 Results

F5, Inc. (NASDAQ: FFIV) posted upbeat earnings for its second quarter and announced plans to reduce its global headcount by approximately 620 employees.

F5, Inc. (NASDAQ:FFIV) posted upbeat earnings for its second quarter and announced plans to reduce its global headcount by approximately 620 employees.

F5 posted quarterly earnings of $2.53 per share, beating analysts’ estimates of $2.42 per share. The company’s quarterly sales came in at $703.00 million, versus expectations of $699.04 million.

F5 shares fell 8.5% to $125.43 in pre-market trading.

These analysts made changes to their price targets on F5 following earnings announcement.

  • Barclays cut the price target on F5 from $166 to $140. Barclays analyst Tim Long downgraded the stock from Overweight to Equal Weight.
  • Piper Sandler lowered the price target on F5 from $156 to $143. Piper Sandler analyst James Fish maintained a Neutral rating.
  • RBC Capital cut the price target on F5 from $155 to $146. RBC Capital analyst Matthew Hedberg maintained the stock with a Sector Perform rating.
  • Credit Suisse slashed the price target on F5 from $166 to $155. Credit Suisse analyst Sami Badri maintained the stock with a Neutral.
  • TD Cowen lowered the price target on F5 from $177 to $170. TD Cowen analyst Paul Silverstein maintained the stock with an Outperform.
  • Morgan Stanley cut the price target on F5 from $175 to $165. Morgan Stanley analyst Meta Marshall maintained an Equal-Weight rating on the stock.

 

Read This Next: Wall Street's Most Accurate Analysts Say Buy These 3 Tech And Telecom Stocks Delivering High-Dividend Yields

Total
0
Shares
Related Posts
Read More

CBD-Focused Avicanna Taps Into European Market Via Exclusive Pharma Supply Deal

Canadian cannabinoid-based biopharmaceutical firm Avicanna will supply two proprietary topical products to an unnamed multinational pharmaceutical firm in six European countries in 2024. The deal will commercialise Avicanna's RHO Phyto brand in Europe for the first time. The company praised its own proprietary patent-protected technologies being entered into "the European market without competition" as testament to its "scientific and technical leadership in the cannabinoid clinical and commercialisation field", highlighting the deal's strategic nature and geographic position, as well as the expected rapid expansion into other European countries. The unnamed pharmaceutical company manufactures and markets a wide range of pharmaceuticals across four continents and has established a commercial infrastructure in Europe. These manufacturing plants will produce Avicanna's Ultra-CBD cream and CBG Transdermal Gel in 2024.

AVCNF